according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Loratadine / Montelukast Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person

responsible for the SDS

: EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

+1-215-631-6999

#### **SECTION 2: Hazards identification**

# 2.1 Classification of the substance or mixture

# Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 H361f: Suspected of damaging fertility.

Long-term (chronic) aquatic hazard, Cat- H411: Toxic to aquatic life with long lasting effects.

egory 2

#### 2.2 Label elements

# Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

¥2

Signal word : Warning

Hazard statements : H361f Suspected of damaging fertility.

H411 Toxic to aquatic life with long lasting effects.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

Precautionary statements : Prevention:

P201 Obtain special instructions before use. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

### Hazardous components which must be listed on the label:

Loratadine

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form combustible dust concentrations in air during processing, handling or other means.

# **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
Chemical name		Classification	
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Montelukast	151767-02-1	Eye Irrit. 2; H319	>= 1 - < 10
Loratadine	79794-75-5	Repr. 2; H361f	>= 3 - < 10
		Aquatic Acute 1;	
		H400	
		Aquatic Chronic 1;	
		H410	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Loratadine / Montelukast Formulation**

Version 2.2	Revision Date: 06.04.2024	SDS Number: 4579030-00012	Date of last issue: 30.09.2023 Date of first issue: 08.07.2019	
			M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

# 4.2 Most important symptoms and effects, both acute and delayed

Risks : Suspected of damaging fertility.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides Metal oxides

### 5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### Loratadine / Montelukast Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 4579030-00012 Date of first issue: 08.07.2019 2.2

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Static electricity may accumulate and ignite suspended dust Technical measures

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation. Advice on safe handling Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures If exposure to chemical is likely during typical use, provide eye

> flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage Do not store with the following product types:

Strong oxidizing agents

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

### **Occupational Exposure Limits**

dusts non-specific 4 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable

dust)

Basis: IE OEL

10 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable

dust)

Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
Montelukast	151767-02- 1	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm <sup>2</sup>	Internal
Loratadine	79794-75-5	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

## **SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

Physical state : tablet

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form combustible dust concentrations in air during pro-

cessing, handling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

# **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form combustible dust concentrations in air during pro-

cessing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

**Components:** 

Montelukast:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 5,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Loratadine:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.05 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

### Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Montelukast:

Species : Rabbit

Result : Mild skin irritation

Loratadine:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Montelukast:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

Species : Rabbit

Result : Severe irritation

Loratadine:

Species : Rabbit

Result : No eye irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

### Respiratory sensitisation

Not classified based on available information.

#### Components:

#### Montelukast:

Remarks : No data available

### Loratadine:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

### Germ cell mutagenicity

Not classified based on available information.

### **Components:**

#### Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

Application Route: Oral

Result: negative

Loratadine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Carcinogenicity

Not classified based on available information.

### **Components:**

### Montelukast:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Result : negative

Loratadine:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 10 mg/kg body weight

Result : positive

Species : Monkey Application Route : Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

Exposure time : 17 Months

NOAEL : 40 mg/kg body weight

Result : negative

### Reproductive toxicity

Suspected of damaging fertility.

### **Components:**

#### Montelukast:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL: 200 mg/kg body weight

Symptoms: Reduced fertility

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: NOAEL: 100 mg/kg body weight

Symptoms: Reduced fertility

### Loratadine:

Effects on fertility : Species: Rat, male

**Application Route: Oral** 

Fertility: LOAEL: 64 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 48 mg/kg body weight

Result: Embryo-foetal toxicity

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 48 mg/kg body weight

Result: Embryo-foetal toxicity

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 12 mg/kg body weight

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and

fertility, based on animal experiments.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

#### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

#### Repeated dose toxicity

#### **Components:**

#### Montelukast:

Species : Monkey, male and female

NOAEL : 150 - 300 mg/kg

Application Route : Oral Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

#### Loratadine:

Species : Rat
NOAEL : 4 mg/kg
LOAEL : 8 mg/kg
Application Route : Oral
Exposure time : 180 Days

Target Organs : Central nervous system

Remarks : Effects are of limited toxicological significance.

Species : Monkey
NOAEL : 0.4 mg/kg
LOAEL : 4 mg/kg
Application Route : Oral
Exposure time : 180 Days

Target Organs : Central nervous system

Remarks : Effects are of limited toxicological significance.

### **Aspiration toxicity**

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

#### 11.2 Information on other hazards

# **Endocrine disrupting properties**

**Product:** 

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### Experience with human exposure

**Components:** 

Montelukast:

Skin contact : Remarks: May irritate skin. Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhoea, Fever

Loratadine:

Ingestion : Symptoms: Fatigue, Headache, dry mouth, Nausea

# **SECTION 12: Ecological information**

# 12.1 Toxicity

### **Components:**

Montelukast:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### Loratadine / Montelukast Formulation

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 06.04.2024 4579030-00012 Date of first issue: 08.07.2019 2.2

Toxicity to microorganisms EC50 : > 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.073 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

NOEC: 0.0816 mg/l Exposure time: 7 d

Species: Cyprinodon variegatus (sheepshead minnow)

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

ic toxicity)

aquatic invertebrates (Chron-

NOEC: 0.23 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Remarks: No toxicity at the limit of solubility

Loratadine:

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.382 mg/l Toxicity to fish

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.83 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.95

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.053

mq/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

1

EC50: > 1,000 mg/l Toxicity to microorganisms

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.084 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Loratadine / Montelukast Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.078 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

1

## 12.2 Persistence and degradability

### **Components:**

Montelukast:

Biodegradability Result: not rapidly degradable

> Biodegradation: 0 % Exposure time: 28 d

Stability in water Hydrolysis: 50 %(21.7 h)

Loratadine:

Biodegradability Result: not rapidly degradable

> Biodegradation: 50 % Exposure time: 20 d

Method: OECD Test Guideline 314

Degradation half life (DT50): 283 d Stability in water

# 12.3 Bioaccumulative potential

#### **Components:**

Montelukast:

Partition coefficient: n-

log Pow: > 4.3

octanol/water Loratadine:

Partition coefficient: n-

log Pow: 2.35

octanol/water

12.4 Mobility in soil

### Components:

Loratadine:

Distribution among environ-

log Koc: 5.25

mental compartments

Method: OECD Test Guideline 106

### 12.5 Results of PBT and vPvB assessment

**Product:** 

Assessment This substance/mixture contains no components considered

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

### 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Loratadine)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Loratadine)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

N.O.S. (Loratadine)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Loratadine)

IATA : Environmentally hazardous substance, solid, n.o.s.

(Loratadine)

14.3 Transport hazard class(es)

Class Subsidiary risks

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

#### 14.4 Packing group

**ADN** 

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**ADR** 

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

**RID** 

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**IMDG** 

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

**ADN** 

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

**RID** 

Environmentally hazardous : yes

**IMDG** 

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

# **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

Not applicable

Quantity 2

500 t

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

Regulation (EC) No 1005/2009 on substances that de- : Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia-

ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Quantity 1
E2 ENVIRONMENTAL 200 t

19/21

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 06.04.2024 4579030-00012 Date of first issue: 08.07.2019

**HAZARDS** 

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H319 : Causes serious eye irritation. H361f : Suspected of damaging fertility.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Aquatic Acute : Short-term (acute) aquatic hazard Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Loratadine / Montelukast Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 06.04.2024
 4579030-00012
 Date of first issue: 08.07.2019

tional Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

### Classification of the mixture:

Classification procedure:

Repr. 2 H361f Calculation method Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN